ADK Hypermethioninemia

ADK hypermethioninemia is a very rare genetic metabolic disorder. It happens when the adenosine kinase (ADK) enzyme does not work well because of changes (mutations) in the ADK gene that you inherit from both parents. ADK normally removes extra adenosine by turning it into AMP. When ADK is weak, adenosine builds up. This buildup pushes the methionine cycle out of balance, so methionine and the related compounds S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine (AdoHcy) rise in blood. The result is hypermethioninemia (high methionine) with liver problems, brain and development problems, and sometimes seizures and unusual facial features. Newborns and infants often show jaundice, cholestasis, high liver enzymes, and low muscle tone, but some children present later mainly with neurological signs. A methionine-restricted diet can help many patients, especially when started early, but there is no curative drug yet; care is supportive and guided by a metabolic specialist. PubMed Central+1PubMedOrpha.net

ADK hypermethioninemia is a very rare, inherited metabolic disease. It happens when the ADK gene does not work well. The ADK gene makes an enzyme called adenosine kinase, which recycles adenosine and helps run the methionine cycle—a pathway your body uses to make and control many important chemicals. When adenosine kinase is weak or missing, adenosine builds up, S-adenosylhomocysteine (AdoHcy) goes high, methylation reactions slow down, and methionine in blood becomes high (hypermethioninemia). Babies and children can have liver problems, developmental delay, low muscle tone, and seizures. Some have a typical facial look (frontal bossing, big head, wide-set eyes). Brain MRI may show delayed myelination or other white-matter changes. The condition is autosomal recessive, so a child is affected when they get one faulty copy of ADK from each parent. Diagnosis relies on blood amino acids (high methionine), special metabolites (high AdoMet/AdoHcy, often normal homocysteine), and ADK gene testing. PubMed CentralOrpha.netPubMed+1

Other names

Hypermethioninemia encephalopathy due to adenosine kinase deficiency, Adenosine kinase (ADK) deficiency, OMIM #614300, ADK-related hypermethioninemia.
All of these names describe the same disorder: a purine–methionine pathway disease caused by loss of ADK enzyme activity. The most visible laboratory sign is persistent high methionine with elevated AdoMet and AdoHcy, usually normal homocysteine, and varying liver dysfunction. The clinical picture combines early liver disease (often neonatal cholestasis), neurologic symptoms (hypotonia, developmental delay, seizures), and mild dysmorphic features. Because it is so rare, many cases are first suspected when unexplained hypermethioninemia is discovered on amino-acid testing. National Organization for Rare DisordersPubMed Central

Types

There is no official subtype classification, but published cases support helpful clinical groupings:

1. Hepatic-predominant, transient course – marked neonatal/infant cholestasis and transaminase rise that may improve over months, with variable later neurologic signs. PubMed

2. Hepatic-severe, life-threatening – early liver failure or persistent severe dysfunction. PubMed

3. Neuro-predominant – milder liver labs but global developmental delay, hypotonia, epilepsy are prominent. SpringerLink

4. Vascular-involved (rare) – arterial tortuosity and even stroke reported in isolated patients. Wiley Online Library

5. Imaging-defined – MRI shows delayed myelination/white-matter changes that may evolve with time. PubMed

6. Genotype-correlated – missense vs frameshift/splice variants; severity and course may vary by mutation, but data remain limited (very small numbers). ScienceDirect

Causes

In ADK hypermethioninemia, the root cause is biallelic pathogenic variants in the ADK gene. The items below explain how that defect leads to disease and what can temporarily worsen the biochemical imbalance. Where items describe “worsening,” they are modifiers, not independent diseases.

1. Biallelic ADK mutations (autosomal recessive) → low/absent adenosine kinase activity. This is the primary cause. PubMed Central

2. Failure to phosphorylate adenosine → adenosine accumulation and disturbed adenosine/AMP “futile cycle.” PubMed

3. Shift of AdoHcy hydrolase equilibrium → AdoHcy rises, a strong methylation inhibitor. Thieme

4. Global methylation slowdown → broad cellular dysfunction; contributes to neurologic and hepatic signs. PubMed Central

5. Upstream methionine-cycle backup → AdoMet and methionine increase in blood. PubMed Central

6. Neonatal hepatic immaturity → amplifies cholestasis and enzyme elevations early in life. PubMed

7. Intercurrent infection/fever → raises metabolic stress; can worsen liver enzymes and methionine levels (reported during decompensations). SpringerLink

8. High dietary methionine/protein load (e.g., some formulas) → pushes methionine levels higher when ADK is deficient. Flore

9. Fasting/catabolic stress → increases endogenous protein breakdown and methionine release. (General principle noted in methylation disorders; applied clinically in ADK series.) Flore

10. Liver injury of any cause (e.g., cholestasis) → reduces methionine handling and accentuates hypermethioninemia in ADK deficiency. PubMed

11. Certain supplements (e.g., SAMe/methionine) → may worsen metabolite excess if given unknowingly. (Avoidance advised in methylation disorders.) Wiley Online Library

12. Consanguinity → increases chance of homozygous ADK variants in families. SpringerLink

13. Missense variants with residual activity → milder biochemical noise but persistent hypermethioninemia. (Genotype–phenotype inference from case reports.) ScienceDirect

14. Truncating/frameshift variants → often more severe enzyme loss and earlier liver disease. ScienceDirect

15. Splice-site defects → abnormal ADK transcript; severity varies by exon/intron involved. ScienceDirect

16. Copy-number changes in ADK locus (rare) → reduced enzyme dosage. (General genetic mechanism for recessive IEMs; rare ADK reports.) ScienceDirect

17. Coexisting methylation-pathway strain (e.g., low methyl donors) → can aggravate symptoms biochemically. (Consensus guidance from methylation disorders extrapolated.) Wiley Online Library

18. Hyperinsulinemic hypoglycemia episodes reported in some patients → stress response that can worsen neurologic status. Wiley Online Library

19. Vascular tortuosity (rare phenotype) → can lead to cerebrovascular events, amplifying neurologic morbidity. Wiley Online Library

20. Delayed recognition/misdiagnosis → prolonged exposure to high AdoHcy/AdoMet and methionine, leading to cumulative organ effects. Frontiers

Symptoms and signs

1. Prolonged newborn jaundice or pale stools – due to cholestasis when the liver cannot process bile normally. PubMed

2. Enlarged liver (hepatomegaly) – a doctor can feel a big liver on exam; it reflects inflammation or fat change. PubMed

3. High liver enzymes (ALT/AST) with or without high bilirubin – a lab clue to liver stress. PubMed

4. Low muscle tone (hypotonia) – the baby feels “floppy,” and motor milestones come late. PubMed

5. Developmental delay – slower progress in sitting, walking, speech, and learning. Frontiers

6. Seizures/epilepsy – brief staring, stiffening, or convulsions, often starting in infancy. SpringerLink

7. Sleepiness or encephalopathy during illness – when sick, the child can become extra drowsy or confused. PubMed Central

8. Feeding difficulty and poor weight gain – due to low tone and liver illness in early months. PubMed

9. Facial features – frontal bossing, macrocephaly, hypertelorism, flat nasal bridge may be seen. MalaCards

10. Tremor or abnormal movements – from brain network irritation when metabolites are high. PubMed Central

11. Irritability or lethargy – nonspecific but common when the liver is inflamed. PubMed

12. Stroke-like symptoms (rare) – sudden weakness or speech trouble from arterial tortuosity/stroke in isolated reports. Wiley Online Library

13. Big head size (macrocephaly) – often noted during well-child checks. Medlink

14. Abnormal brain MRI – delayed myelination or later white-matter changes; sometimes central tegmental tract signals. PubMed

15. Intermittent hypoglycemia (some cases) – can cause sweating, shakiness, or seizures. Wiley Online Library

Diagnostic tests

A) Physical examination (bedside)

1. General growth and nutrition check – weight/length/head size help spot failure to thrive or macrocephaly, guiding further testing. Medlink

2. Skin and eye color for jaundice – yellowing suggests cholestasis and raises suspicion for metabolic liver disease. PubMed

3. Abdominal palpation – detects hepatomegaly, steering work-up toward liver-related causes of hypermethioninemia. PubMed

4. Neurologic tone and reflexes – low tone and delayed reflexes support a neuro-metabolic disorder. PubMed

5. Dysmorphology assessment – looks for frontal bossing, hypertelorism, depressed nasal bridge, which, while not specific, fit the pattern. MalaCards

B) “Manual” clinical tests (simple clinic procedures)

6. Developmental screening (e.g., milestones checklist) – documents global delay to justify metabolic testing. Frontiers

7. Liver span measurement (tape/percussion) – tracks objective changes in liver size during illness or treatment. PubMed

8. Bedside neurologic maneuvers (tone grading, pull-to-sit, head control) – quantify hypotonia and truncal weakness. PubMed

9. Dietary review – identifies high-methionine/protein exposures that may worsen labs and symptoms. Flore

10. Family pedigree/consanguinity check – supports autosomal-recessive inheritance and guides genetic counseling. SpringerLink

C) Laboratory & pathological tests

11. Plasma amino acids – high methionine is the key screening clue; homocysteine often normal in ADK deficiency. PubMed

12. AdoMet and AdoHcy levels (plasma) – both elevated; AdoHcy is a direct marker of methylation block. National Organization for Rare Disorders

13. Liver panel (ALT, AST, bilirubin, GGT, INR/albumin) – defines the severity of hepatopathy/cholestasis. PubMed

14. Glucose/insulin profile – looks for hyperinsulinemic hypoglycemia, reported in several patients. Wiley Online Library

15. Genetic testing of the ADK gene (sequencing ± CNV) – confirmatory test that identifies the biallelic pathogenic variants. Frontiers

16. (Optional) Enzyme/biomarker studies (e.g., adenosine in dried blood spot, research use) – explored as future newborn-screening markers. Flore

17. Liver biopsy (selected cases) – may show steatosis/cholestasis; used when diagnosis is unclear and other causes must be ruled out. ResearchGate

D) Electrodiagnostic tests

18. EEG – evaluates epileptiform activity in infants with seizures; helps guide anti-seizure care. SpringerLink

19. ECG (and echocardiogram if needed) – checks for cardiac anomalies reported in some case cohorts. Medlink

E) Imaging tests

20. Brain MRI (± MR spectroscopy) – typical findings include delayed but eventually completed myelination and later nonspecific white-matter changes; MRS may show reduced choline. PubMed
    Supplemental imaging often used: Liver ultrasound for size/texture and bile flow; vascular imaging when tortuosity or stroke is suspected. PubMedWiley Online Library

Non-pharmacological treatments

Foundation note: The only disease-specific intervention with evidence is a methionine-restricted diet supervised by a metabolic team. It aims to lower methionine and secondarily AdoMet/AdoHcy, which may improve liver labs and neurodevelopment in many—but not all—patients. PubMed CentralThieme

1. Medical nutrition therapy: methionine-restricted diet
   Description: A metabolic dietitian calculates daily methionine needs by age/weight. Natural protein from meat, fish, eggs, and legumes is limited to a personalized allowance. The core calories come from low-methionine foods plus a medical amino-acid formula that supplies all essential amino acids except methionine and adds cysteine (which becomes essential when methionine is low). Fats and carbohydrates are balanced to support growth. Fluids are optimized to avoid catabolic stress. Families learn food weighing, exchange lists, and sick-day rules. Regular labs (plasma amino acids; AdoMet/AdoHcy when available) guide step-down or step-up adjustments.
   Purpose: Lower the methionine load to a safe range; stabilize liver function and neurodevelopment.
   Mechanism: Less dietary methionine → reduced substrate flow into AdoMet/AdoHcy pool → improved methylation balance.
   Benefits: Often improves liver enzymes, reduces decompensation episodes, and may support better development when started early. PubMed Central

2. Sick-day plan (catabolism prevention)
   Description: During fever, vomiting, or poor intake, families use a written plan: increase fluids, provide extra carbohydrates (e.g., oral glucose polymers), temporarily reduce natural protein, and seek early medical care if unable to maintain intake.
   Purpose: Prevent catabolism that raises endogenous methionine.
   Mechanism: Carbohydrate loading limits protein breakdown.
   Benefits: Fewer hospitalizations and smoother recovery. PubMed Central

3. Breastfeeding/formula optimization
   Description: Maintain breastfeeding if possible, but blend with measured low-methionine formula under dietitian guidance to hit daily methionine targets.
   Purpose: Support growth while controlling methionine.
   Mechanism: Precise methionine delivery.
   Benefits: Normal growth, better lab control. PubMed Central

4. Fat-soluble vitamin repletion in cholestasis (A, D, E, K) – nutrition route
   Description: In cholestasis, dietary absorption of A/D/E/K is poor. Specialized vitamin preparations and adequate dietary fat (including MCT when indicated) are provided.
   Purpose: Prevent rickets, neuropathy, coagulopathy.
   Mechanism: Corrects deficiency from bile flow problems.
   Benefits: Better bone, nerve, and bleeding health. PubMed

5. Feeding therapy (SLP/OT)
   Description: Therapists address suck-swallow coordination, texture progression, and safe intake; consider thickened feeds or gastrostomy if needed (see surgeries).
   Purpose: Ensure adequate calories and safe swallowing.
   Mechanism: Skill training and positioning.
   Benefits: Fewer aspiration events, steady growth. PubMed Central

6. Physiotherapy for hypotonia
   Description: Core and proximal strengthening, supported sitting/standing, and motor-milestone programs (tummy time → crawling → walking aids).
   Purpose: Improve posture and mobility.
   Mechanism: Neuroplasticity and muscle conditioning.
   Benefits: Faster motor gains and fewer contractures. Orpha.net

7. Occupational therapy (fine motor and daily skills)
   Description: Hand control, bimanual tasks, self-care routines (feeding, dressing), adaptive seating/utensils.
   Purpose: Independence in daily life.
   Mechanism: Task-specific learning.
   Benefits: Better function and caregiver relief. Orpha.net

8. Speech-language therapy
   Description: Early communication supports, augmentative tools if needed, and oromotor work.
   Purpose: Improve speech and language outcomes.
   Mechanism: Repetitive practice and cueing.
   Benefits: Better interaction and learning. Orpha.net

9. Early-intervention education program
   Description: Structured play-based learning, individualized educational plan, and therapy integration.
   Purpose: Maximize cognitive development.
   Mechanism: Enriched environment during critical periods.
   Benefits: Improved school readiness. Orpha.net

10. Caregiver training & coaching
    Description: Practical instruction on formula preparation, weighing foods, reading labels, and recognizing warning signs.
    Purpose: Empower families to manage at home.
    Mechanism: Skills transfer and troubleshooting.
    Benefits: Fewer errors and emergencies. PubMed Central

11. Genetic counseling
    Description: Explain inheritance (autosomal recessive), recurrence risks, and options for family testing/prenatal diagnosis.
    Purpose: Informed family planning.
    Mechanism: Risk communication and testing pathway.
    Benefits: Earlier diagnosis in future pregnancies/siblings. Thieme

12. Sleep hygiene and routine scheduling
    Description: Regular sleep and meal timing reduce catabolic swings and seizure risk.
    Purpose: Metabolic stability.
    Mechanism: Circadian and energy balance.
    Benefits: Fewer bad days and better learning. SpringerLink

13. Vaccination on time
    Description: Keeps infections low; check vitamin K status if cholestatic.
    Purpose: Reduce illness-triggered decompensation.
    Mechanism: Immune protection.
    Benefits: Fewer ER visits. PubMed Central

14. Illness-prevention hygiene bundle
    Description: Hand-washing, sick contacts avoidance, early fever management, hydration goals.
    Purpose/Mechanism/Benefits: Lower infection burden → fewer metabolic crises. PubMed Central

15. Pruritus self-care in cholestasis
    Description: Skin emollients, cool baths, cotton clothing, sleep scheduling; escalate to meds if needed (see drugs).
    Purpose: Comfort and sleep.
    Mechanism: Non-drug itch control.
    Benefits: Better quality of life. PubMed

16. Moderate-fat, energy-adequate diet planning (beyond methionine limits) – keeps calories sufficient to avoid catabolism. PubMed Central

17. MCT-inclusive nutrition when bile flow is poor – easier fat absorption. PubMed

18. Safety plan for seizures – first-aid steps, rescue meds access. SpringerLink

19. Orthopedic/physio co-management for hip dysplasia and hypotonia seating. Thieme

20. Vision/hearing supports if sensory issues occur (glasses, therapy, aids). Thieme

21. School accommodations – fatigue-aware scheduling, diet logistics at school. Orpha.net

22. Developmental surveillance every 3–6 months – adjust therapies promptly. Orpha.net

23. Medication review to avoid hepatotoxins – see drugs section. Medlink

24. Regular lab monitoring protocol – amino acids, LFTs, INR, vitamins. PubMed Central

25. Family peer-support connection – coping strategies and adherence tips. Orpha.net

Drug treatments

Important: There is no curative medicine for ADK deficiency. Drug therapy is supportive (for liver disease, seizures, cholestasis, nutrition) and must fit the methionine-restricted diet plan. Avoid hepatotoxic drugs when possible (notably valproate for seizures). ThiemeMedlink

1. Levetiracetam (antiepileptic; 10–60 mg/kg/day in 2 doses)
   Time/Purpose: Continuous for seizure control.
   Mechanism: Modulates synaptic vesicle protein SV2A to stabilize neuronal firing.
   Side effects: Somnolence, irritability; rare mood changes. Liver-safe profile favored in metabolic liver disease. SpringerLink

2. Lamotrigine (antiepileptic; start ~0.3 mg/kg/day; slow titration to effect)
   Purpose: Focal/generalized seizures alternative.
   Mechanism: Voltage-gated sodium channel blocker; reduces glutamate release.
   Side effects: Rash (rare SJS/TEN—slow titration reduces risk); dizziness. Preferred over valproate when liver is fragile. SpringerLink

3. Clobazam (or diazepam) as rescue (benzodiazepine; intermittent)
   Purpose: Abort prolonged seizures/cluster.
   Mechanism: GABA-A positive modulation.
   Side effects: Sedation, tolerance. Use per neurologist plan. SpringerLink

4. Ursodeoxycholic acid (UDCA) (choleretic; 10–15 mg/kg/day ÷ 2–3)
   Purpose: Improve cholestasis flow, lessen itch, support enzymes.
   Mechanism: Hydrophilic bile acid replaces toxic species, promotes bile flow.
   Side effects: Loose stools; monitor LFTs. PubMed

5. Fat-soluble vitamin A (retinol; specialized pediatric formulations; dose per level)
   Purpose: Correct deficiency.
   Mechanism: Repletes stores needed for vision/immune integrity.
   Side effects: Hypervitaminosis A if overdosed—strict level-guided dosing. PubMed

6. Vitamin D (cholecalciferol; deficiency-based dosing)
   Purpose: Bone mineralization in cholestasis.
   Mechanism: Raises 25-OH-D.
   Side effects: Hypercalcemia if excessive; monitor labs. PubMed

7. Vitamin E (water-miscible tocopherol; dose per weight/levels)
   Purpose: Neurologic protection; antioxidant in cholestasis.
   Mechanism: Replaces poorly absorbed fat-soluble vitamin.
   Side effects: Gastro upset; monitor INR if very high doses. PubMed

8. Vitamin K (1–5 mg oral/IV per coagulation status)
   Purpose: Correct prolonged INR due to cholestasis.
   Mechanism: Supports γ-carboxylation of clotting factors.
   Side effects: Injection site pain (IM avoided in coagulopathy); anaphylactoid with rapid IV—hospital protocols apply. PubMed

9. Cholestyramine (bile acid sequestrant; ~240 mg/kg/day ÷ 2–3; max per guidelines)
   Purpose: Second-line anti-pruritus.
   Mechanism: Binds bile acids in gut → less itch signaling.
   Side effects: Constipation, poor absorption of other meds/vitamins—time doses apart. PubMed

10. Rifampin (enzyme inducer; specialist-directed for refractory itch)
    Purpose: Third-line anti-pruritus in cholestasis.
    Mechanism: Enhances bile acid metabolism and pruritogen clearance.
    Side effects: Hepatotoxicity potential—only with close LFT monitoring. PubMed

11. Phenobarbital (as choleretic adjunct in select infants; dosing per weight)
    Purpose: Promote bile flow in neonatal cholestasis (historical/selected use).
    Mechanism: Enzyme induction.
    Side effects: Sedation; behavioral effects; monitor LFTs. Use only if benefits outweigh risks. PubMed

12. Medium-chain triglyceride (MCT) oil (medical food but often prescribed)
    Purpose: Caloric support when fat absorption is poor.
    Mechanism: Bypasses bile-dependent absorption; rapid energy.
    Side effects: GI upset; titrate slowly. PubMed

13. AquADEKs or equivalent multivitamin for cholestasis (prescription-grade)
    Purpose: Bundled A/D/E/K with absorption enhancers.
    Mechanism: Matches malabsorption pattern.
    Side effects: As per components; lab-guided dosing. PubMed

14. N-acetylcysteine (NAC) (off-label hepatoprotective; hospital protocols)
    Purpose: Antioxidant support during acute hepatic stress.
    Mechanism: Glutathione precursor.
    Side effects: Nausea; rare anaphylactoid infusion reactions—specialist use only; evidence in ADK is limited. Medlink

15. Avoid/replace valproate (antiepileptic)
    Purpose: Safety measure—choose alternatives.
    Mechanism: Valproate can injure mitochondria/liver; avoid in cholestatic/metabolic liver disease.
    Side effects: Hepatotoxicity, hyper-ammonemia—reason to avoid here. Medlink

Dietary molecular supplements

Caution: Some common “methylation” supplements are contraindicated. For example, betaine (trimethylglycine) converts homocysteine to methionine and can raise methionine, so it is not used in ADK hypermethioninemia unless a separate indication exists. SAMe is already high—do not supplement it. Always individualize. Wiley Online Library

1. Cysteine (as L-cystine in medical formulas) – Dose: built into low-Met formulas per age. Function: replaces sulfur amino acids when methionine is restricted. Mechanism: supplies downstream sulfur without raising methionine. PubMed Central

2. Medical amino-acid mix (Met-free) – Dose: per diet prescription. Function: complete protein without methionine. Mechanism: maintains growth while lowering methionine exposure. PubMed Central

3. MCT oil – Dose: titrated tablespoons/day. Function: energy in cholestasis. Mechanism: bile-independent absorption. PubMed

4. Vitamin A – Dose: per measured level. Function/Mechanism: fat-soluble vitamin repletion; immune/vision integrity. PubMed

5. Vitamin D – Dose: per deficiency table. Function: bone; Mechanism: raises 25-OH-D. PubMed

6. Vitamin E – Dose: water-miscible form per kilogram. Function: antioxidant neural protection in cholestasis. Mechanism: replaces deficient tocopherol. PubMed

7. Vitamin K – Dose: per INR/levels. Function: correct coagulopathy. Mechanism: restores clotting factor γ-carboxylation. PubMed

8. Zinc – Dose: per dietitian/levels. Function: growth, appetite, immunity. Mechanism: trace element repletion in chronic cholestasis. PubMed

9. Selenium – Dose: per level. Function: antioxidant enzyme cofactor. Mechanism: supports glutathione peroxidase. PubMed

10. Taurine – Dose: specialist-guided. Function: bile acid conjugation support; may aid fat absorption. Mechanism: forms tauro-conjugated bile acids. Evidence is limited; use only with specialist oversight. PubMed

Immunity-booster / regenerative / stem-cell drugs

At present, there are no proven immunity boosters, regenerative drugs, or stem-cell drugs that treat ADK deficiency itself. Some children have undergone liver transplantation for severe liver failure (rarely needed), but this is surgery, not a drug, and it does not correct the enzyme in all tissues (brain). Experimental gene or cell therapies for ADK deficiency have not reached clinical use. The safest path is dietary therapy + supportive care and enrollment in a clinical registry or study when available. PubMedPubMed Central

Surgeries

1. Liver transplantation – Procedure: replace the failing liver with a donor liver. Why: acute or progressive liver failure unresponsive to medical care. Note: may improve liver labs but does not cure brain involvement. PubMed Central

2. Gastrostomy tube (G-tube) – Procedure: feeding tube through the abdomen. Why: persistent unsafe swallow or inadequate oral intake to meet precise diet targets. PubMed Central

3. Central venous line (temporary) – Procedure: IV access for decompensation care. Why: deliver fluids/NAC/meds safely during crises. Medlink

4. Orthopedic surgery for hip dysplasia – Procedure: as per pediatric ortho protocols. Why: improve joint stability and mobility. Thieme

5. Cochlear implant/ENT procedures (selected cases) – Why: if significant hearing loss is confirmed. Thieme

Preventions (practical)

1. Early diagnosis and diet start. Thieme

2. Regular clinic + lab monitoring (AAs, LFTs, vitamins). PubMed Central

3. Written sick-day plan to avoid catabolism. PubMed Central

4. Vaccinations and infection control. PubMed Central

5. Avoid hepatotoxic drugs; coordinate with all prescribers. Medlink

6. Diet accuracy (weigh foods; correct formula prep). PubMed Central

7. Hydration goals daily. PubMed Central

8. Growth tracking with timely diet up-titration. PubMed Central

9. Therapy intensity (PT/OT/SLP) to prevent secondary disability. Orpha.net

10. Family genetic counseling for future pregnancies. Thieme

When to see doctors

• Immediately / ER: persistent vomiting, poor intake > 6–8 hours, fever with lethargy, worsening jaundice, pale stools, dark urine, bleeding/bruising, breathing trouble, seizure > 5 minutes, repeated seizures, or any concern for dehydration. PubMed

• Urgent clinic within 24–48 h: new rash while starting a seizure medicine, marked itching, new swelling of abdomen, poor weight gain, or confusion. SpringerLink

• Routine metabolic/hepatic follow-up: growth checks, diet adjustments, amino-acid/liver labs every 1–3 months in infancy (then spaced as stable). PubMed Central

What to eat and what to avoid

1. Eat: the prescribed low-methionine formula and measured natural protein allowance—this is the heart of therapy. Avoid: “eyeballing” protein portions. PubMed Central

2. Eat: fruits, many vegetables, low-protein starches as directed. Avoid: high-protein foods (red meat, poultry, fish, eggs, legumes) beyond your allowance. PubMed Central

3. Eat: oils and, if advised, MCT for calories. Avoid: unplanned fasting. PubMed

4. Take: A/D/E/K and any trace minerals as prescribed. Avoid: skipping vitamin doses in cholestasis. PubMed

5. Drink: extra fluids on sick days per plan. Avoid: dehydration. PubMed Central

6. Choose: school/restaurant options that fit your exchanges. Avoid: hidden protein in broths/sauces. PubMed Central

7. Use: a kitchen scale or app. Avoid: guesswork. PubMed Central

8. Confirm: supplements with the metabolic team. Avoid: betaine or SAMe products (can worsen methionine chemistry). Wiley Online Library

9. Store: a sick-day carb drink at home. Avoid: running out during illness. PubMed Central

10. Coordinate: diet with therapists/school caregivers. Avoid: missed formula doses during therapy days. Orpha.net

FAQs

1. Is ADK hypermethioninemia the same as “primary hypermethioninemia”?
   No. Several rare disorders cause high methionine. ADK deficiency is one of them; others include MAT1A, GNMT, and AHCY defects. Genetic testing tells them apart. Cell

2. Will my child outgrow it?
   No. It is genetic. But many children improve with a low-methionine diet and good supportive care. PubMed Central

3. Can the liver normalize?
   Yes, some infants’ liver disease improves over time, especially with early diet; a few develop severe failure. Close follow-up is key. PubMed

4. Why not give SAMe or betaine to help methylation?
   In ADK deficiency, AdoMet (SAMe) and AdoHcy are already high; betaine raises methionine further. These are not routine treatments. Wiley Online Library

5. What blood tests matter the most?
   Plasma methionine, AdoMet/AdoHcy (where available), full liver panel, INR, and fat-soluble vitamins. Wiley Online LibraryPubMed Central

6. Is homocysteine high?
   Often normal in ADK deficiency—this helps distinguish it from other methylation problems. Thieme

7. Do all patients have seizures?
   No. Some do; others mainly have liver issues or developmental delay. SpringerLink

8. Are there new treatments coming?
   Research is active, but as of September 8, 2025, care remains diet-centered + supportive; rare case reports describe transplant for severe liver failure. PubMed Central+1

9. Can adults be diagnosed?
   Yes—some are diagnosed later after years of unexplained liver/neurological issues. PubMed Central

10. What about coffee/caffeine (adenosine pathways)?
    No proven disease-specific effect; follow age-appropriate guidance and focus on the prescribed diet. Liebert Publishing

11. Is tall stature part of the disease?
    Not typical, but reported in single cases along with hip dysplasia. Thieme

12. Could heart defects be related?
    They have been reported in some patients; evaluation is individualized. MalaCards

13. Why does the diet include cysteine?
    When methionine is restricted, cysteine becomes essential; providing it supports growth without raising methionine. PubMed Central

14. How often do we check labs?
    Often every 1–3 months in infancy, then as advised when stable. PubMed Central

15. What should schools know?
    Your child needs scheduled formula/foods, seizure safety planning if applicable, and flexibility for medical visits. Orpha.net

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.

Previous

Adenosine Kinase Deficiency (ADK Deficiency)

Next

Autosomal Recessive Intellectual Disability (ARID)

Related Articles

Added to wishlistRemoved from wishlist 1

Caudal Appendage-Deafness Syndrome

Added to wishlistRemoved from wishlist 1

Cathepsin A-related Arteriopathy-Strokes-Leukoencephalopathy (CARASAL)

Added to wishlistRemoved from wishlist 1

Pierre Robin Sequence–Hyperphalangy–Clinodactyly Syndrome

Added to wishlistRemoved from wishlist 1

Palatodigital Syndrome, Catel-ManzkeType